Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
Moodys
Chubb
US Army
Colorcon
US Department of Justice
Mallinckrodt
Boehringer Ingelheim

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,472,373

« Back to Dashboard

Which drugs does patent 6,472,373 protect, and when does it expire?

Patent 6,472,373 protects REBETOL and is included in two NDAs.

Protection for REBETOL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-six patent family members in twenty-six countries.
Summary for Patent: 6,472,373
Title: Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Abstract:Methods for treating an antiviral treatment naive patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving administering a therapeutically effective amount of a combination therapy of ribavirin and interferon-alpha for a time period of from 20 up to 50 weeks are disclosed.
Inventor(s): Albrecht; Janice K. (Winter Park, FL)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/311,487
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,472,373

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-001 Jun 3, 1998 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-002 Jul 25, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering REBETOL ribavirin SOLUTION;ORAL 021546-001 Jul 29, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,472,373

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,172,046 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Chubb
McKinsey
Harvard Business School
Daiichi Sankyo
Dow
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.